PCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0a/8c/1d/0a8c1d3d-d7d3-834d-7e15-4d148fbf0970/mza_667160144501362064.jpg/600x600bb.jpg

Lipid Luminations

ReachMD

174 episodes

4 months ago

Get to the heart of the most recent advances in lipid management and cardiovascular disease with Lipid Luminations, which features scientific and clinical research updates, novel emerging treatment options, and best practices in patient care.

Science

Medicine

RSS

All content for Lipid Luminations is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

PCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects

Lipid Luminations

9 years ago

PCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine.

Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.